Thermo Fisher’s second quarter saw a notable uptick in end-market activity, propelling results above Wall Street’s expectations and leading to a positive market reaction. Management pointed to stronger demand across pharmaceutical, biotech, industrial, and diagnostics markets, with CEO Marc Casper highlighting “broad-based momentum” and “excellent execution” in core segments such as Bioproduction and Clinical Research. Newly launched high-end instruments and AI-powered software were key contributors, helping the company capture greater market share and further embed itself as a partner of choice for scientific and healthcare customers.

Is now the time to buy TMO? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Thermo Fisher’s Q2 Earnings Call

• Michael Ryskin (Bank of America) asked about the drivers behind broad-based improvement across end markets. CEO Marc Casper pointed to stronger customer activity and a notable rebound in biotech, stating that “customer activity picked up across our end markets.”
• Tycho Peterson (JPMorgan) inquired about the performance of clinical research (including Clario and PPD) and Patheon. Casper explained that “clinical research really had an excellent quarter” and described improving market conditions, while modest growth in Patheon was in line with expectations.
• Jack Meehan (Nephron Research) sought detail on pharma and biotech spending, specifically inventory and reshoring effects. Casper described the quarter as “clean,” emphasizing broad-based momentum in bioproduction and research channels, and highlighted that “biotech recovery” was visible in results.
• Matthew Larew (William Blair) asked about Analytical Instruments and the impact of recent product launches. Casper attributed growth to “relevant innovation,” noting strong global adoption of new high-end instruments and AI-enabled offerings, and cited robust bookings in electron microscopy.
• Daniel Arias (Stifel) queried the performance of the Chemical Analysis segment and macro-sensitive businesses. Casper identified higher commodity prices and increased demand for safety and security applications, such as radiation detection, as primary growth drivers for the segment.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will watch for (1) sustained improvement in pharma and biotech spending and whether this translates into continued organic growth, (2) successful integration and revenue realization from recent acquisitions like Clario, and (3) execution of the microbiology divestiture and redeployment of capital into innovation and shareholder returns. Progress on new product uptake and global market expansion will also be key indicators.

Thermo Fisher currently trades at $573.25, up from $526.46 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.